UK Markets open in 40 mins

Zynerba Pharmaceuticals, Inc. (0M40.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
3.2600-0.1100 (-3.26%)
At close: 04:26PM GMT

Zynerba Pharmaceuticals, Inc.

80 West Lancaster Avenue
Suite 300
Devon, PA 19333
United States
484 581 7505
http://zynerba.com

Sector(s)
Industry
Full-time employees26

Key executives

NameTitlePayExercisedYear born
Mr. Armando Anido MBAChairman & CEO902.08kN/A1958
Ms. Terri B. SebreePres686.79kN/A1958
Mr. James E. FickenscherCFO, VP of Corp. Devel. & Treasurer582.82kN/A1964
Ms. Suzanne M. HanlonSec., VP & Gen. CounselN/AN/A1957
Dr. Joseph PalumboChief Medical OfficerN/AN/AN/A
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. It focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It improves the lives of patients and their families living with severe, chronic health conditions, including Fragile X syndrome, autism spectrum disorder, 22q11.2 deletion syndrome, and a heterogeneous group of rare and ultra-rare epilepsies known as developmental and epileptic encephalopathies. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania.

Corporate governance

Zynerba Pharmaceuticals, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.